Table.
Regression Results for Changes in the Rate of Fillsa
| Overall fills |
Days supply (d) |
Daily dose (mg) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acamp |
BUP |
NTX OUD |
NTX AUD |
1-7 |
8-15 |
16-27 |
28+ |
0-7.9 |
8-11.9 |
12-15.9 |
16+ |
|
| Rate ratio | ||||||||||||
| All | ||||||||||||
| COVID-19 | 1.03 (0.98-1.08) | 1.03 (0.99-1.06) | 1.13 (0.99-1.30) | 0.98 (0.95-1.01) | 0.91b (0.83-1.00) | 1.10c (1.05-1.15) | 0.94 (0.88-1.01) | 1.06c (1.03-1.08) | 0.99 (0.95-1.02) | 0.94c (0.92-0.97) | 1.11d (1.04-1.18) | 1.08c (1.03-1.12) |
| Change in training | 1.05b (1.00-1.10) | 0.97 (0.95-1.00) | 1.15 (0.98-1.35) | 1.06c (1.03-1.09) | 0.86c (0.79-0.93) | 1.00 (0.96-1.04) | 1.05 (0.98-1.11) | 1.00 (0.98-1.02) | 1.01 (0.98-1.05) | 1.06c (1.03-1.10) | 0.94b (0.89-0.99) | 0.94c (0.91-0.97) |
| Elimination of X-Waiver | 1.11c (1.06-1.16) | 1.03 (1.00-1.06) | 1.14 (0.95-1.37) | 1.05d (1.02-1.08) | 0.99 (0.90-1.08) | 1.02 (0.98-1.07) | 1.04 (0.98-1.11) | 1.05c (1.02-1.07) | 1.06d (1.02-1.10) | 1.06c (1.03-1.10) | 1.04 (0.98-1.10) | 1.00 (0.97-1.04) |
| Com. | ||||||||||||
| COVID-19 | 0.98 (0.93-1.03) | 1.06b (1.01-1.11) | 1.03 (0.83-1.26) | 0.99 (0.96-1.04) | 0.94 (0.82-1.07) | 1.15d (1.05-1.26) | 0.97 (0.89-1.05) | 1.07c (1.04-1.10) | 1.01 (0.96-1.06) | 0.98 (0.95-1.01) | 1.15d (1.06-1.26) | 1.12d (1.03-1.23) |
| Change in training | 1.01 (0.96-1.06) | 0.98 (0.93-1.03) | 1.05 (0.80-1.38) | 1.06d (1.02-1.10) | 0.84b (0.72-0.98) | 0.98 (0.88-1.08) | 1.02 (0.93-1.11) | 1.01 (0.98-1.04) | 1.03 (0.98-1.09) | 1.06d (1.02-1.11) | 0.93 (0.85-1.02) | 0.93 (0.85-1.01) |
| Elimination of X-Waiver | 1.07b (1.01-1.13) | 1.03 (0.97-1.08) | 1.05 (0.74-1.49) | 1.04b (1.00-1.08) | 0.99 (0.83-1.18) | 1.02 (0.90-1.15) | 1.07 (0.97-1.18) | 1.03 (1.00-1.06) | 1.06 (1.00-1.13) | 1.04 (0.99-1.09) | 1.02 (0.92-1.12) | 1.00 (0.92-1.09) |
| MA | ||||||||||||
| COVID-19 | 1.12 (0.99-1.28) | 0.98 (0.96-1.01) | 1.21 (0.95-1.55) | 0.92d (0.87-0.98) | 0.91 (0.81-1.01) | 1.01 (0.97-1.06) | 0.92b (0.86-0.98) | 1.03d (1.01-1.06) | 1.00 (0.95-1.05) | 0.89c (0.85-0.94) | 0.99 (0.94-1.04) | 1.00 (0.97-1.03) |
| Change in training | 1.10 (0.99-1.21) | 0.96c (0.94-0.98) | 1.49c (1.19-1.86) | 1.04 (1.00-1.08) | 0.86c (0.79-0.94) | 0.98 (0.94-1.01) | 1.05 (1.00-1.11) | 1.00 (0.98-1.02) | 0.93c (0.90-0.96) | 1.00 (0.96-1.04) | 0.93c (0.90-0.97) | 0.97d (0.95-0.99) |
| Elimination of X-Waiver | 1.19c (1.08-1.30) | 1.02 (1.00-1.04) | 1.37d (1.10-1.69) | 1.02 (0.99-1.06) | 0.99 (0.91-1.07) | 1.02 (0.98-1.05) | 1.01 (0.96-1.06) | 1.06c (1.04-1.08) | 1.00 (0.97-1.03) | 1.02 (0.98-1.06) | 1.06d (1.02-1.10) | 1.02 (1.00-1.04) |
a
Acamp, acamprosate; AUD, alcohol use disorder; BUP, buprenorphine; OUD, opioid use disorder; MA, Medicare Advantage; NTX, naltrexone.
b
P<.05.
c
P<.001.
d
P<.01.